Roivant Sciences Ltd.
NASDAQ:ROIV
11.39 (USD) • At close June 27, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 29.053 | 124.795 | 61.28 | 55.286 | 23.795 | 67.689 |
| Cost of Revenue
| 0.911 | 27.964 | 13.128 | 8.966 | 2.057 | 1.131 |
| Gross Profit
| 28.142 | 96.831 | 48.152 | 46.32 | 21.738 | 66.558 |
| Gross Profit Ratio
| 0.969 | 0.776 | 0.786 | 0.838 | 0.914 | 0.983 |
| Reseach & Development Expenses
| 550.413 | 501.736 | 525.215 | 483.035 | 236.626 | 263.217 |
| General & Administrative Expenses
| 591.41 | 0 | 600.506 | 775.033 | 259.878 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 591.41 | 675.039 | 600.506 | 775.033 | 259.878 | 335.766 |
| Other Expenses
| -110.387 | -5,321.96 | 97.749 | 139.894 | 596.132 | 0 |
| Operating Expenses
| 1,031.436 | -4,132.781 | 1,223.47 | 1,397.962 | 1,092.636 | 598.983 |
| Operating Income
| -1,003.294 | 4,242.016 | -1,175.318 | -1,351.642 | -1,070.898 | -532.425 |
| Operating Income Ratio
| -34.533 | 33.992 | -19.179 | -24.448 | -45.005 | -7.866 |
| Total Other Income Expenses Net
| 321.704 | 11.414 | -49.516 | 427.895 | 172.351 | -28.561 |
| Income Before Tax
| -681.59 | 4,253.43 | -1,224.834 | -923.747 | -898.547 | -560.986 |
| Income Before Tax Ratio
| -23.46 | 34.083 | -19.988 | -16.709 | -37.762 | -8.288 |
| Income Tax Expense
| 48.174 | 22.224 | 5.19 | 0.369 | 1.686 | 7.124 |
| Net Income
| -171.981 | 4,348.926 | -1,009.03 | -845.262 | -809.234 | 1,200.509 |
| Net Income Ratio
| -5.92 | 34.849 | -16.466 | -15.289 | -34.009 | 17.736 |
| EPS
| -0.237 | 5.55 | -1.42 | -1.26 | -1.18 | 5.21 |
| EPS Diluted
| -0.237 | 5.23 | -1.42 | -1.26 | -1.18 | 5.21 |
| EBITDA
| -1,099.61 | 4,310.244 | -1,178.009 | -916.706 | -895.738 | -553.303 |
| EBITDA Ratio
| -37.848 | 34.539 | -19.223 | -16.581 | -37.644 | -8.174 |